Teva Pharma (TEVA) Tops Q2 EPS by 2c, Affirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Teva Reports Second Quarter 2020 Financial Results
August 5, 2020 7:00 AM EDTRevenues of $3.9 billion GAAP diluted EPS of $0.13 Non-GAAP diluted EPS of $0.55 Free cash flow of $582 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2020.
This press release features multimedia. View the full... More
